Oculis Holding AG OCS
NASDAQ OCS
$12.17 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Oculis Holding AG (OCS) Cash from Financing Activities (2022 - 2026)

Oculis Holding AG (OCS) posted quarterly Cash from Financing Activities of $30.1 million for Q1 2026, down 73.9% year-over-year from $115.5 million in Q1 2025, and down 71.39% quarter-over-quarter from $105.3 million in Q4 2025.

Analysis

Oculis Holding AG (OCS) Cash from Financing Activities (2022 - 2026) Analysis & Trends

Oculis Holding AG's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $30.1 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities fell 73.9% year-over-year to $30.1 million; the TTM figure through Mar 2026 stood at $134.1 million (down 23.41% YoY), while the FY2025 annual figure was $225.4 million, up 267.45% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $30.1 million, down from $105.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $115.5 million in Q1 2025, with the low at -$2.1 million in Q3 2025.
  • The 5-year median for Cash from Financing Activities is $2.0 million (2022), against an average of $30.2 million.
  • The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 264.05% in 2024, then jumped 58848.04% in 2025.
  • Oculis Holding AG's Cash from Financing Activities stood at -$288570.1 in 2022, then jumped by 264.08% to $473488.9 in 2023, then jumped by 549.73% to $3.1 million in 2024, then jumped by 3324.12% to $105.3 million in 2025, then sank by 71.39% to $30.1 million in 2026.
  • Business Quant data shows OCS's Cash from Financing Activities at $30.1 million in Q1 2026, $105.3 million in Q4 2025, and -$2.1 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Oculis Holding AG 634.75 Mn 345.87 Mn - 31.67 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 31.67 Mn
Mar 31, 2026 30.14 Mn
Dec 31, 2025 105.34 Mn
Sep 30, 2025 -2.14 Mn
Jun 30, 2025 730,773.59
Mar 31, 2025 115.49 Mn
Dec 31, 2024 3.08 Mn
Sep 30, 2024 -850,650.74
Jun 30, 2024 57.33 Mn
Mar 31, 2024 195,911.68
Dec 31, 2023 473,488.88
Sep 30, 2023 518,525.87
Jun 30, 2023 37.23 Mn
Mar 31, 2023 103.00 Mn
Dec 31, 2022 -288,570.09
Sep 30, 2022 2.03 Mn